{"name":"Axsome Therapeutics","slug":"axsome","ticker":"AXSM","exchange":"NASDAQ","domain":"axsome.com","description":"Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate rec","hq":"New York, NY","founded":0,"employees":"1220","ceo":"Herriot Tabuteau","sector":"CNS / Neuroscience","stockPrice":232.35,"stockChange":-2.97,"stockChangePercent":-1.26,"marketCap":"$12.0B","metrics":{"revenue":708236032,"revenueGrowth":57.4,"grossMargin":92.6,"rdSpend":183279000,"netIncome":-183174000,"cash":322933000,"dividendYield":0,"peRatio":39.5,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"AXS-07 patent cliff ($0.0B at risk)","drug":"AXS-07","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"AXS-02","genericName":"AXS-02","slug":"axs-02","indication":"Neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN)","status":"phase_3"},{"name":"AXS-05","genericName":"AXS-05","slug":"axs-05","indication":"Major depressive disorder (approved)","status":"marketed"},{"name":"AXS-07","genericName":"AXS-07","slug":"axs-07","indication":"Acute migraine with or without aura","status":"phase_3"},{"name":"AXS-07 (meloxicam-rizatriptan)","genericName":"AXS-07 (meloxicam-rizatriptan)","slug":"axs-07-meloxicam-rizatriptan","indication":"Acute migraine with or without aura","status":"phase_3"},{"name":"AXS-12 (Reboxetine)","genericName":"AXS-12 (Reboxetine)","slug":"axs-12-reboxetine","indication":"Major depressive disorder","status":"phase_3"},{"name":"AXS-14 (Esreboxetine)","genericName":"AXS-14 (Esreboxetine)","slug":"axs-14-esreboxetine","indication":"Major depressive disorder","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AXS-02 (oral zoledronate)","genericName":"AXS-02 (oral zoledronate)","slug":"axs-02-oral-zoledronate","indication":"Osteoporosis","status":"phase_3"}]}],"pipeline":[{"name":"AXS-02","genericName":"AXS-02","slug":"axs-02","phase":"phase_3","mechanism":"AXS-02 is a combination of dextromethorphan and quinidine that enhances NMDA receptor antagonism and sigma-1 receptor modulation to reduce neuropathic pain.","indications":["Neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN)","Fibromyalgia"],"catalyst":""},{"name":"AXS-02 (oral zoledronate)","genericName":"AXS-02 (oral zoledronate)","slug":"axs-02-oral-zoledronate","phase":"phase_3","mechanism":"AXS-02 is an oral formulation of zoledronate, a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.","indications":["Osteoporosis","Bone metastases and hypercalcemia of malignancy (investigational oral formulation)"],"catalyst":""},{"name":"AXS-05","genericName":"AXS-05","slug":"axs-05","phase":"marketed","mechanism":"AXS-05 is a combination of dextromethorphan and bupropion that enhances serotonergic and noradrenergic neurotransmission while modulating NMDA receptor activity.","indications":["Major depressive disorder (approved)","Treatment-resistant depression (approved)"],"catalyst":""},{"name":"AXS-07","genericName":"AXS-07","slug":"axs-07","phase":"phase_3","mechanism":"AXS-07 is a combination of melitracen (a tricyclic compound) and rizatriptan that works synergistically to treat acute migraine by enhancing serotonergic activity and providing rapid symptom relief.","indications":["Acute migraine with or without aura"],"catalyst":""},{"name":"AXS-07 (meloxicam-rizatriptan)","genericName":"AXS-07 (meloxicam-rizatriptan)","slug":"axs-07-meloxicam-rizatriptan","phase":"phase_3","mechanism":"AXS-07 combines meloxicam (an NSAID) with rizatriptan (a 5-HT1B/1D receptor agonist) to treat acute migraine by reducing inflammation and constricting cranial blood vessels.","indications":["Acute migraine with or without aura"],"catalyst":""},{"name":"AXS-12 (Reboxetine)","genericName":"AXS-12 (Reboxetine)","slug":"axs-12-reboxetine","phase":"phase_3","mechanism":"Reboxetine is a selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the brain by blocking its reuptake at the presynaptic neuron.","indications":["Major depressive disorder","Attention-deficit/hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"AXS-14 (Esreboxetine)","genericName":"AXS-14 (Esreboxetine)","slug":"axs-14-esreboxetine","phase":"phase_3","mechanism":"Esreboxetine is a norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the central nervous system by blocking its reuptake at the presynaptic neuron.","indications":["Major depressive disorder","Treatment-resistant depression"],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"regulatory","headline":"FDA Approves AXS-07 for Acute Treatment of Migraine Attacks","summary":"The FDA has approved AXS-07 for the acute treatment of migraine attacks in adults.","drugName":"AXS-07","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Axsome Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Axsome Therapeutics reported its third quarter 2023 financial results, with revenue of $13.4 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQSTdWbXBIWUpabnhEWUdldmFkYnJuTk5OdjlrcGpyYjljX1c4a19YbGFvelRfSVNfOC1KZXlWcWNySlNINngyMnVxZElqelV3Vlk0RnV0cHBlbVY3RFpSekl2SXdSN3ktT051czNRaGMyVlhpdEw1Nll5NzJqTjBjZGZwX3VhUTZJZTB6QjQzTDhpbmdaWUlhSjNlSmo4dDlDbkRuZUZMcHNCZ2hWT1pxSHQ5QlRXUQ?oc=5","date":"2026-04-01","type":"deal","source":"Benzinga","summary":"Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda - Benzinga","headline":"Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda","sentiment":"neutral"},{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-26","type":"pipeline","source":"simplywall.st","summary":"Is It Time To Reassess Axsome Therapeutics (AXSM) After Mixed Recent Share Price Moves - simplywall.st","headline":"Is It Time To Reassess Axsome Therapeutics (AXSM) After Mixed Recent Share Price Moves","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-14","type":"regulatory","source":"simplywall.st","summary":"A Look At Axsome Therapeutics (AXSM) Valuation As Legal Probe And FDA Decision Draw Investor Focus - simplywall.st","headline":"A Look At Axsome Therapeutics (AXSM) Valuation As Legal Probe And FDA Decision Draw Investor Focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNdUU3bW9mTFRoU1JHVXVuUHpQZjZIWFRpeUhtZnlnR2NxNFBuT1VydXJMM3RVNV9pWUE5VUNCNFNFWDE0R3hZc2UzaGo0X3dNRjhHXy1TOTJicF8zNkwwNmR5dkE0XzhZME1vd3RXVWNjNHlTUVV4ZFN1N1ZqNWJSalYwb2ttdklEd2Fr?oc=5","date":"2026-03-10","type":"deal","source":"The Motley Fool","summary":"2 Under-the-Radar Stocks to Buy and Hold - The Motley Fool","headline":"2 Under-the-Radar Stocks to Buy and Hold","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQOXNNbW1uRFJubmo5NllhTGVEOVFCUHNlN29ZZ0tBeE0yZVZaTF80d1Q2dW1ncVRQdFdMU2JvV1BSRHRaNjQ3UjhhRzNlSFNobEdQT3o5MS1IR2o5YTdSanBUcDFVZk1jUzFUR1V3eUZnYjdxWDd5d3B5ZVExalZpZmxFZTFYRkhNMDQ3V29OQXFDT1hWZk1xSUdpMkZLek5Qa21IcnBGZk90M20yN2JxUE9ibzZZNzA3WE56UWJyT21PamthRlZlaDY1Ml9JYXRHWnBKcQ?oc=5","date":"2026-02-23","type":"pipeline","source":"FinancialContent","summary":"Axsome Therapeutics (AXSM): A CNS Powerhouse at a Commercial Crossroad - FinancialContent","headline":"Axsome Therapeutics (AXSM): A CNS Powerhouse at a Commercial Crossroad","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQMlV6SlhmYm5KRURpbWh4TzRzcmJxZHBqUUd4LWJiekJzRXBFUlJ3Ti1BNXA5U3F0clhobHRRc0EwTEdsRzhkSUdBY1hfRVJpTWEyZkdkSWVhU1c2QUk1cmlrVlJvY2hUcXVXNkNQZlpuRzdyS0VENUU1SmowVFZKcDI3U3hCcEFJaWJOUEZhYkJndWF0VGpNVFlzMlZueWtrcW5TNG5lWmJjbUYwZ05BUmpFNWEwZw?oc=5","date":"2026-02-23","type":"earnings","source":"Seeking Alpha","summary":"Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued (AXSM) - Seeking Alpha","headline":"Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued (AXSM)","sentiment":"neutral"},{"date":"2026-02-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQUzJDQTRnQ2pOU0JoUUJRT2YxYm9Qc3hIaFY4WktwR09HeDFLaVRCQ0dRRzF4RHJ1RnN3cTFVUFUyVzVjVFJjZmpuS3VCbTlpQ1RTQi1OcnhPWFZ1ZUJWTHpDN1hwbW51UGlBdUlFU3NrYzdXSWRob1Y0Q3F1QUs3c3dNcl9sNU16amtjT2lB?oc=5","date":"2026-02-05","type":"pipeline","source":"The Motley Fool","summary":"Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool","headline":"Best Biotech Stocks of 2026 and How to Invest in Them","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNQnQzcWtIT2d2VFlpRUgycjlveGRuc01TOEZnS1BpUV9zV1l2M2dMQmF0XzRfdkF6OHdvcWMwRlVlQnlZS1ozTDVCaVFEWkhSMGFkTl8zMl8wamgxQVJpT1h2VXpnRVRzU3JWcUJzVXpjRUFScGx4cE9YZ0NyOFprQWpuUWNRYmwxYTFxNWhDaVhsNGhaYzFR?oc=5","date":"2026-01-04","type":"regulatory","source":"Yahoo Finance","summary":"Axsome Therapeutics (AXSM): Reassessing Valuation After Key FDA Milestones for AXS-05 and AXS-12 - Yahoo Finance","headline":"Axsome Therapeutics (AXSM): Reassessing Valuation After Key FDA Milestones for AXS-05 and AXS-12","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOUDAtY2l5QmNva0w0V1BBbEpSblhNbzdQaTVIVXN5aUVlYlZwZm1XQWlrd2tKeUJxcElubE1jZnRxRWlqX1U2bUxPREJ5MDJuZWtXMHc0OVliTWdWbHF1ZFpFb3BNVHJjOXJPOTR3Z01uWU9pdkhNd3ZvNWNNdW1sT0tub0RHdXA1dFlaLXQ0R2psbU1ucVBnUTZCLWxZLUdTVnRJenZFTzlKTTE1em8tX1l1V0NsbFRjQXFCag?oc=5","date":"2026-01-01","type":"regulatory","source":"TechStock²","summary":"Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug - TechStock²","headline":"Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOVTZLNnVJcHV3NVBmNXU0NHVqa1BWNC0xckp0cGxCWUFGSDFnYlV6MjJJTzNpQTQxOWJUZy1TV0V1UlByZDVacF95c0ZLM3hWcXlPay15d3Y4X1lSamE5ZURmM1hzNUZTclQ1RklvU1I4Y1pBTkRFRXFNZ2IwM2M5eUd5WHlvZHRCelN5cXpCN1p5M1hQcnB0Vnd3eU41ZW9ReVE?oc=5","date":"2025-12-31","type":"pipeline","source":"Seeking Alpha","summary":"Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - Seeking Alpha","headline":"Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOTUNkYktPSXFvaVZ1UVN3ekY1bUdNRGVpR1FhS3o2V2pnNVFJU091WTBNS2NsTENBUElIeVRZWW5sbGdWZklKRmxRUHhoTmxyOWdBc2p3V0xDbWpjT3hFV1dDQ1lsaDA3RkdUSWJfQ0FnZzB6VDJLQTh5ODktcExCdEg4RVU3blZBYW91Y3NjMEtFaml1c1VjN3lmb2ExcjFxdlg2NjVwZDhGTGNtUmVMTzZiVVVxQzMydXc?oc=5","date":"2025-12-31","type":"regulatory","source":"TechStock²","summary":"Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing - TechStock²","headline":"Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing - TechStock²","sentiment":"neutral"}],"patents":[{"drugName":"AXS-07","drugSlug":"dextromethorphan-and-metaxalone","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":7,"phaseCounts":{"phase_3":6,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Allergan","Eli Lilly","Pfizer"],"therapeuticFocus":["Migraine","Depression","Anxiety"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":0,"period":"2022-12-31"}],"grossProfit":591018000,"grossProfitHistory":[{"period":"2025-12-31","value":591018000},{"period":"2024-12-31","value":352390000},{"period":"2023-12-31","value":244535000},{"period":"2022-12-31","value":44839000}],"rdSpend":183279000,"rdSpendHistory":[{"period":"2025-12-31","value":183279000},{"period":"2024-12-31","value":187077000},{"period":"2023-12-31","value":97944000},{"period":"2022-12-31","value":57947000}],"sgaSpend":570599000,"operatingIncome":-169235000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-169235000},{"period":"2024-12-31","value":-252438000},{"period":"2023-12-31","value":-182907000},{"period":"2022-12-31","value":-176501000}],"netIncome":-183174000,"netIncomeHistory":[{"period":"2025-12-31","value":-183174000},{"period":"2024-12-31","value":-287216000},{"period":"2023-12-31","value":-239238000},{"period":"2022-12-31","value":-187134000}],"eps":-3.68,"epsHistory":[{"period":"2025-12-31","value":-3.68},{"period":"2024-12-31","value":-5.99},{"period":"2023-12-31","value":-5.27},{"period":"2022-12-31","value":-4.6}],"cash":322933000,"cashHistory":[{"period":"2025-12-31","value":322933000},{"period":"2024-12-31","value":315353000},{"period":"2023-12-31","value":386193000},{"period":"2022-12-31","value":200842000}],"totalAssets":689805000,"totalLiabilities":601510000,"totalDebt":218113000,"equity":88295000,"operatingCashflow":-93405000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-93405000},{"period":"2024-12-31","value":-128410000},{"period":"2023-12-31","value":-145080000},{"period":"2022-12-31","value":-116511000}],"capex":-480000,"capexHistory":[{"period":"2025-12-31","value":-480000},{"period":"2024-12-31","value":-270000},{"period":"2023-12-31","value":-582000},{"period":"2022-12-31","value":-702000}],"freeCashflow":-93885000,"dividendsPaid":null,"buybacks":null,"employees":1220,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":184996000,"ebit":-63357000,"ebitda":-60990000,"period":"2026-03-31","revenue":191203000,"epsBasic":-1.26,"netIncome":-64542000,"rdExpense":52677000,"epsDiluted":-1.26,"grossProfit":176478000,"operatingIncome":-62767000},{"sga":169297000,"ebit":-26957000,"ebitda":-24683000,"period":"2025-12-31","revenue":195999000,"epsBasic":-0.56,"netIncome":-28559000,"rdExpense":48791000,"epsDiluted":-0.56,"grossProfit":183670000,"operatingIncome":-36025000},{"sga":150235000,"ebit":-46109000,"ebitda":-43698000,"period":"2025-09-30","revenue":170992000,"epsBasic":-0.94,"netIncome":-47229000,"rdExpense":40162000,"epsDiluted":-0.94,"grossProfit":159080000,"operatingIncome":-32924000},{"sga":130280000,"ebit":-47099000,"ebitda":-44853000,"period":"2025-06-30","revenue":150042000,"epsBasic":-0.97,"netIncome":-47973000,"rdExpense":49541000,"epsDiluted":-0.97,"grossProfit":136594000,"operatingIncome":-44816000},{"sga":120787000,"ebit":-56982000,"ebitda":-54849000,"period":"2025-03-31","revenue":121463000,"epsBasic":-1.22,"netIncome":-59413000,"rdExpense":44785000,"epsDiluted":-1.22,"grossProfit":111674000,"operatingIncome":-55470000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":232.35,"previousClose":235.32,"fiftyTwoWeekHigh":235.91,"fiftyTwoWeekLow":96.09,"fiftyTwoWeekRange":"96.09 - 235.915","fiftyDayAverage":180.36,"twoHundredDayAverage":152.23,"beta":0.58,"enterpriseValue":12024305664,"forwardPE":39.5,"priceToBook":218.79,"priceToSales":16.88,"enterpriseToRevenue":16.98,"enterpriseToEbitda":-71.9,"pegRatio":0,"ebitda":-167234000,"ebitdaMargin":-23.6,"freeCashflow":-3851750,"operatingCashflow":-70730000,"totalDebt":219900000,"debtToEquity":402.8,"currentRatio":1.39,"returnOnAssets":-16.8,"returnOnEquity":-349.4,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":21,"targetMeanPrice":270.28,"targetHighPrice":328.81,"targetLowPrice":200,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":15.4,"institutionHeldPercent":77.1,"sharesOutstanding":51459766,"floatShares":43546283,"sharesShort":2748577,"shortRatio":3.89,"shortPercentOfFloat":5.3,"epsTrailing":-3.72,"epsForward":5.89,"revenuePerShare":14.07,"bookValue":1.06,"officers":[{"age":57,"name":"Dr. Herriot  Tabuteau M.D.","title":"Founder, Chairman, CEO & President"},{"age":50,"name":"Mr. Nick  Pizzie CPA, M.B.A.","title":"Chief Financial Officer"},{"age":42,"name":"Mr. Mark L. Jacobson M.A.","title":"Chief Operating Officer"},{"age":45,"name":"Mr. Hunter  Murdock Esq.","title":"General Counsel & Secretary"},{"age":46,"name":"Mr. Ari  Maizel M.B.A.","title":"Chief Commercial Officer"},{"age":null,"name":"Darren  Opland","title":"Director of Corporate Communications"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.axsome.com","phone":"212 332 3241"}}